Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21038725 | 0.78 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL295502 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL14538319 | 0.76 | ALDH1A1 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2MAPK1 | |
| SCHEMBL13770854 | 0.75 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL6184745 | 0.74 | SLC6A2 (0.51) | SLC6A2SLC6A4 | |
| SCHEMBL392115 | 0.73 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL18475299 | 0.73 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12339308 | 0.72 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1087374 | 0.72 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25619700 | 0.72 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2013-11-28 | — | — | US | disclosed |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-7750002-B2 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | SLC6A2 3406/4885SLC6A4 2575/4885SLC6A3 1887/4885 |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | SLC6A2 3406/4885SLC6A4 2575/4885SLC6A3 1887/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | SLC6A2 3701/4885SLC6A4 3499/4885SLC6A3 3925/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | SLC6A2 1959/4885SLC6A4 2105/4885SLC6A3 2079/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | SLC6A2 3408/4885SLC6A4 2558/4885SLC6A3 1894/4885 |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | SLC6A2 3406/4885SLC6A4 2575/4885SLC6A3 1887/4885 |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | SLC6A2 3406/4885SLC6A4 2575/4885SLC6A3 1887/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | SLC6A2 1959/4885SLC6A4 2105/4885SLC6A3 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.